Balstilimab: all 41 studies that test it
Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingNCT07735624Phase 2
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3RecruitingNCT07595874Phase 2
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingNCT07551596Phase 2
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingNCT07550088Phase 2
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingNCT07516366Phase 2
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingNCT07227636Phase 2
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingNCT07193862Early Phase 1
- Botensilimab, Balstilimab, and SBRT in Colorectal CancerRecruitingNCT07128355Early Phase 1
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingNCT06843551Phase 2
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingNCT06843434Phase 2
- A Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabRecruitingNCT06782555Phase 1/2
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryRecruitingNCT06780787Phase 2
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingNCT06411691Phase 1
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingNCT06346197Phase 3
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingNCT06336902Phase 1
- Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)RecruitingNCT05891821Phase 2
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGRecruitingNCT04943848Phase 1
- Combination Immunotherapy in Colorectal CancerCompletedNCT05571293Phase 2Results posted
- AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder CancerTerminatedNCT04430036Phase 2Results posted
- A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)CompletedNCT03495882Phase 1/2Results posted
- A Study of AGEN2034 in Advanced Tumors and Cervical CancerCompletedNCT03104699Phase 1/2Results posted
- Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal AdenocarcinomaTerminatedNCT07152821Phase 3
- Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)Active, not recruitingNCT06322108Phase 2
- Botensilimab and Balstilimab Optimization in Colorectal CancerActive, not recruitingNCT06268015Phase 2
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingNCT06251973Phase 2
- The Seven Trial: Exploiting the Unfolded Protein ResponseTerminatedNCT06076837Phase 1
- Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and NeckTerminatedNCT05930951Phase 1
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedNCT05928806Phase 2
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
- Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingNCT05672316Phase 1/2
- Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic CancerActive, not recruitingNCT05638698Phase 2
- FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingNCT05627635Phase 1/2
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingNCT05608044Phase 2
- BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer PatientsWithdrawnNCT05363709Phase 2
- Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersActive, not recruitingNCT05205330Phase 1/2
- A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerWithdrawnNCT05033132Phase 2
- Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)WithdrawnNCT04943627Phase 3
- A Study in Subjects With Advanced Solid TumorsTerminatedNCT04156100Phase 1
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasActive, not recruitingNCT04028063Phase 2
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingNCT03860272Phase 1